<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Obes Surg</journal-id><journal-id journal-id-type="iso-abbrev">Obes Surg</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Obesity Surgery</journal-title></journal-title-group><issn pub-type="ppub">0960-8923</issn><issn pub-type="epub">1708-0428</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11717886</article-id><article-id pub-id-type="pmcid-ver">PMC11717886.1</article-id><article-id pub-id-type="pmcaid">11717886</article-id><article-id pub-id-type="pmcaiid">11717886</article-id><article-id pub-id-type="pmid">39636519</article-id><article-id pub-id-type="doi">10.1007/s11695-024-07602-w</article-id><article-id pub-id-type="publisher-id">7602</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Obesity-Related Kidney Disease in Bariatric Surgery Candidates</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Pereira</surname><given-names initials="PR">Pedro Reis</given-names></name><address><email>pedroreisper@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Almeida</surname><given-names initials="M">Manuela</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Braga</surname><given-names initials="P">Patr&#237;cia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pereira</surname><given-names initials="J">Jo&#227;o</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pereira</surname><given-names initials="S">Sofia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nora</surname><given-names initials="M">M&#225;rio</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guimar&#227;es</surname><given-names initials="M">Marta</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Malheiro</surname><given-names initials="J">Jorge</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martins</surname><given-names initials="LS">La Salete</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Monteiro</surname><given-names initials="MP">Mariana P.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names initials="A">Anabela</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Department of Nephrology, Unidade Local de Sa&#250;de de Santo Ant&#243;nio, (ULS Santo Ant&#243;nio), Porto, Portugal </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043pwc612</institution-id><institution-id institution-id-type="GRID">grid.5808.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1503 7226</institution-id><institution>Unit for Multidisciplinary Research in Biomedicine (UMIB), School of Medicine and Biomedical Sciences (ICBAS), </institution><institution>University of Porto, </institution></institution-wrap>Porto, Portugal </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043pwc612</institution-id><institution-id institution-id-type="GRID">grid.5808.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1503 7226</institution-id><institution>ITR - Laboratory for Integrative and Translational Research in Population Health, </institution></institution-wrap>Porto, Portugal </aff><aff id="Aff4"><label>4</label>General Surgery Department and CRI for the surgical Treatment of Obesity and Metabolic Diseases, ULS Entre o Douro e Vouga, Santa Maria da Feira, Portugal </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>35</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">479146</issue-id><fpage>181</fpage><lpage>188</lpage><history><date date-type="received"><day>21</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>9</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>22</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>11</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-11 00:25:16.507"><day>11</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="11695_2024_Article_7602.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Obesity has a negative impact in kidney health. However, the hallmarks of kidney dysfunction in bariatric surgery candidates are poorly characterized. To address this knowledge gap, we used a propensity score-matched analysis to compare kidney lesion biomarkers in bariatric surgery candidates and living kidney donors.</p></sec><sec><title>Methods</title><p id="Par2">Bariatric surgery candidates attending a single center for obesity treatment were pair-matched for sex and age to potential living kidney transplant donors (PLKD) using a 1:1 nearest-neighbor approach (<italic toggle="yes">N</italic>&#8201;=&#8201;400, <italic toggle="yes">n</italic>&#8201;=&#8201;200/group). A 24-h urine collection was used to analyze proteinuria and creatinine clearance.</p></sec><sec><title>Results</title><p id="Par3">Patients with obesity (PWO) had higher creatinine clearance when compared to PLKD (143.35&#8201;&#177;&#8201;45.50&#160;mL/min vs 133.99&#8201;&#177;&#8201;39.06&#160;mL/min, <italic toggle="yes">p</italic>&#8201;=&#8201;0.03), which was underestimated when correction for body surface area (BSA) was used (creatinine clearance corrected for BSA of 115.25&#8201;&#177;&#8201;33.63&#160;mL/min/1.73 m<sup>2</sup> in PWO vs 135.47&#8201;&#177;&#8201;35.56&#160;mL/min/1.73 m<sup>2</sup> in PLKD). Proteinuria was also higher in PWO compared to PLKD (139.82&#8201;&#177;&#8201;353.258&#160;mg/day vs 136.35&#8201;&#177;&#8201;62.24&#160;mg/day, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001). Regression analysis showed that creatinine clearance was strongly correlated with proteinuria in PWO (HR 1.522, <italic toggle="yes">p</italic>&#8201;=&#8201;0.005), but it was less evident in PLKD (HR 0.376, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001).</p></sec><sec><title>Conclusion</title><p id="Par4">Hyperfiltration and disproportionate proteinuria are frequent in patients with obesity. Since hyperfiltration can be underestimated by adjusting creatinine clearance for BSA, this should not be used when evaluating kidney function in bariatric surgery candidates.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Fatty kidney</kwd><kwd>Hyperfiltration</kwd><kwd>Living kidney donation</kwd><kwd>Proteinuria</kwd><kwd>Obesity-related glomerulopathy</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universidade do Porto</institution></funding-source></award-group><open-access><p>Open access funding provided by FCT|FCCN (b-on).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Obesity has significant repercussions on kidney health [<xref ref-type="bibr" rid="CR1">1</xref>]. Obesity leads to the progression of chronic kidney disease (CKD) irrespective of the underlying etiology and causes specific kidney disorders, such as obesity-related glomerulopathy [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par6">Hyperfiltration, frequently observed in the setting of obesity, is believed to play a significant role in the development of obesity-related kidney disorders [<xref ref-type="bibr" rid="CR2">2</xref>]. Other possible kidney lesion pathways include tubulointerstitial dysfunction with excess tubular sodium reabsorption, overactivation of the renin&#8211;angiotensin&#8211;aldosterone system, and renal sympathetic nervous system [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>]. Additionally, adipose tissue-derived hormones [<xref ref-type="bibr" rid="CR9">9</xref>] and pro-inflammatory adipokines, such as leptin, resistin, fetuin-A, angiopoietins, vascular endothelial growth factor (VEGF), cathepsins, cystatin-C, and reactive oxygen species (ROS), can also have a negative impact on kidney function [<xref ref-type="bibr" rid="CR10">10</xref>]. Free fatty acids (FFAs) derived from perirenal fat accumulation have been also shown to damage the kidney cortex and tubules [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Altogether, these factors may trigger an adaptative systemic response favoring ectopic lipid accumulation and fibrogenesis that results in tubuloglomerular injury [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>], similar to what is observed in the liver [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par7">Evaluating kidney function in patients with obesity (PWO) can be challenging. To account for body size differences, estimated glomerular filtration rate (eGFR) formulas usually correct the glomerular filtration value for body surface area (BSA). However, since eGFR does not increase in parallel with adiposity, being rather the end result of the increase of single nephron filtration, indexing creatinine clearance for BSA ends up concealing hyperfiltration in patients with obesity [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. This has previously been demonstrated in a study comparing the performance of 56 formulas based on creatinine and/or cystatin C with measured GFR [<xref ref-type="bibr" rid="CR19">19</xref>], suggesting that BSA indexing should generally be abandoned in PWO.</p><p id="Par8">Living donor kidney transplantation is the best available treatment for end-stage CKD [<xref ref-type="bibr" rid="CR20">20</xref>]. Potential living kidney donor (PLKD) candidates are routinely screened for health conditions that are contraindications for kidney donation by living individuals[<xref ref-type="bibr" rid="CR21">21</xref>]. This process allows to exclude individuals found to have overt kidney function abnormalities among an overall healthy population.</p><p id="Par9">In this study, we sought to compare kidney function markers of individuals with or without obesity recruited among candidates for bariatric surgery or living kidney donation. Because sex and age are known to be important determinants of both kidney function and body composition [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], we used propensity matching to identify the individuals included in the analysis in order to minimize the differences in baseline characteristics between groups.</p></sec><sec id="Sec2"><title>Materials and Methods</title><sec id="Sec3"><title>Patients</title><p id="Par10">This study included patients with obesity (PWO) recruited among bariatric surgery candidates attending a center for surgical treatment of obesity between 2019 and 2022 and another group without obesity recruited among individuals attending a center for evaluation of living kidney transplant donors (PLKD) candidates between 2008 and 2019.</p><p id="Par11">In the first group, patients were adults eligible for surgical treatment of obesity with body mass index (BMI) higher than 40&#160;kg/m<sup>2</sup> or with BMI higher than 35&#160;kg/m<sup>2</sup> in the presence of obesity-related comorbidities. In the second group, subjects had been validated as living kidney transplant donors. Criteria to be admitted as a living kidney donor followed the Kidney Disease: Improving Global Outcomes (KDIGO) 2017 clinical practice guideline for evaluating living donor candidates [<xref ref-type="bibr" rid="CR24">24</xref>] and the British Guidelines for Living Donor Evaluation [<xref ref-type="bibr" rid="CR25">25</xref>], which are thoroughly described elsewhere [<xref ref-type="bibr" rid="CR21">21</xref>]; in particular, obesity defined by a BMI greater than 30&#160;kg/m<sup>2</sup> is an exclusion criterion. In addition, the concomitant diagnosis of any type of diabetes or prediabetes under treatment with metformin, neoplastic diseases, or acute or chronic inflammatory conditions was pre-established exclusion criteria for both study groups. Donors with proteinuria were further evaluated for glomerular pathology and those with confirmed proteinuria over 300&#160;mg/day were also excluded. Normal glycemic status was defined as a glycated hemoglobin level under 5.7% in the absence of any antidiabetic medication; prediabetes was defined as a glycated hemoglobin level between 5.7 and 6.5% and no antidiabetic drugs other than metformin; diabetes was defined as a glycated hemoglobin level greater than 6.5% or treatment with two or more different anti-diabetic drug classes, regardless of the glycated hemoglobin levels.</p></sec><sec id="Sec4"><title>Data Acquisition</title><p id="Par12">Data concerning age, gender, body weight, BMI, complete blood count, serum creatinine, uric acid levels, fasting glucose, hemoglobin, lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides), urinalysis, proteinuria, and indexed and non-indexed creatinine clearance based on a 24-h urine collection were acquired for each patient. CKD-EPI 2021 Creatinine was used to calculate the estimated glomerular filtration rate (eGFR) [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par13">The study participants were instructed to collect a 24-h urine on two consecutive days before the blood sampling. Individuals were given oral and written instructions on how to perform a 24-h urine collection. Urinary protein and creatinine concentrations were measured in each collection. The 24-h creatinine clearance rate was calculated using the measured serum creatinine concentration and the urine creatinine concentration of the 24-h urine; measurements were calculated both in body surface area (BSA)-indexed and non-indexed forms [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par14">Participants were categorized into clinically significant levels of proteinuria (higher or lower than 150&#160;mg/24&#160;h) as defined by the KDIGO guidelines [<xref ref-type="bibr" rid="CR28">28</xref>]. A threshold of creatinine clearance of 140&#160;mL/min was used to classify patients as having significant hyperfiltration [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par15">The study protocol was reviewed and approved by the ethical committees and institutional review boards of both hospital institutions (approvals no. CA-014/20-Ot_MP/CC and 147&#8211;21(119-DEFI/122-CE) in accordance with the recommendations of the Declaration of Helsinki and European Data Protection Regulations.</p></sec><sec id="Sec5"><title>Propensity Matching</title><p id="Par16">The XLSTAT extension of Microsoft Excel was used to perform a propensity matching between members of both groups according to sex and age. The original data set had 238 individuals in the PWO group and 365 individuals in the PLKD group. One-to-one matching was performed using the Mahalanobis distance technique.</p></sec><sec id="Sec6"><title>Statistical Analysis</title><p id="Par17">All data presented are expressed as mean&#8201;&#177;&#8201;standard deviation (SD), unless otherwise specified. The Shapiro&#8211;Wilk test was used to determine the normality of the groups. A comparison of independent groups was carried out by using either an unpaired <italic toggle="yes">t</italic>&#8208;test or a Mann&#8211;Whitney <italic toggle="yes">U</italic> test, depending on the normality. To compare 2 or more nominal variables, we used a <italic toggle="yes">&#967;</italic>2 test. To assess relative risk increase/adjusted odds ratios a linear or a binary logistic regression, depending on the variable&#8217;s type, was employed using SPSS version 28.0, either by using single or combined variables. The prediction power of different parameters was evaluated using the receiver operating characteristic (ROC) curve. The area under the ROC curve (AUC) was used to measure how well a marker can predict outcome measures. Based on the AUC, the test was considered excellent between 0.90 and 1.00, good between 0.80 and 0.90, fair between 0.70 and 0.80, and poor between 0.60 and 0.70, and the test was considered to have failed if the value was below 0.60. A <italic toggle="yes">p</italic>&#8208;value&#8201;&lt;&#8201;0.05 was considered statistically significant. Statistical analysis was carried out using GraphPad (Prism; Version 8.0.1) and SPSS (IBM; Version 28.0) for Windows.</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par18">Propensity matching returned 200 individuals in each study group of PWO and PLKD, yielding a final population of 400 individuals. Clinical and biochemical characteristics of the participants are depicted in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. Variables related to kidney function are presented in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. BMI was significantly different between groups (41.70&#8201;&#177;&#8201;5.32&#160;kg/m<sup>2</sup> in PWO vs 24.91&#8201;&#177;&#8201;3.32&#160;kg/m<sup>2</sup> in PLKD; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001) (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Clinical and biochemical characteristics in each study group. Results are presented as mean&#8201;&#177;&#8201;standard deviation (SD)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">PWO</th><th align="left" colspan="1" rowspan="1">PLKD</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">41.70&#8201;&#177;&#8201;5.32</td><td align="left" colspan="1" rowspan="1">24.91&#8201;&#177;&#8201;3.32</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1">41.93&#8201;&#177;&#8201;11.40</td><td align="left" colspan="1" rowspan="1">43.81&#8201;&#177;&#8201;10.18</td><td align="left" colspan="1" rowspan="1">0.084</td></tr><tr><td align="left" colspan="1" rowspan="1">Female, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">161 (80.5)</td><td align="left" colspan="1" rowspan="1">156 (78.0)</td><td align="left" colspan="1" rowspan="1">0.622</td></tr><tr><td align="left" colspan="1" rowspan="1">Uric acid (mg/dL)</td><td align="left" colspan="1" rowspan="1">5.59&#8201;&#177;&#8201;1.32</td><td align="left" colspan="1" rowspan="1">4.21&#8201;&#177;&#8201;1.22</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">Glucose (mg/dL)</td><td align="left" colspan="1" rowspan="1">92.20&#8201;&#177;&#8201;11.65</td><td align="left" colspan="1" rowspan="1">84.59&#8201;&#177;&#8201;8.52</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">Hemoglobin (g/dL)</td><td align="left" colspan="1" rowspan="1">13.81&#8201;&#177;&#8201;1.15</td><td align="left" colspan="1" rowspan="1">13.72&#8201;&#177;&#8201;1.20</td><td align="left" colspan="1" rowspan="1">0.20</td></tr><tr><td align="left" colspan="1" rowspan="1">Total cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">193.82&#8201;&#177;&#8201;36.07</td><td align="left" colspan="1" rowspan="1">189.48&#8201;&#177;&#8201;37.83</td><td align="left" colspan="1" rowspan="1">0.31</td></tr><tr><td align="left" colspan="1" rowspan="1">Triglycerides (mg/dL)</td><td align="left" colspan="1" rowspan="1">125.17&#8201;&#177;&#8201;62.48</td><td align="left" colspan="1" rowspan="1">93.40&#8201;&#177;&#8201;50.45</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">HDL cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">49.13&#8201;&#177;&#8201;10.91</td><td align="left" colspan="1" rowspan="1">62.98&#8201;&#177;&#8201;16.17</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">LDL cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">133.22&#8201;&#177;&#8201;36.22</td><td align="left" colspan="1" rowspan="1">109.81&#8201;&#177;&#8201;31.74</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid-lowering therapy, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">18 (9.0)</td><td align="left" colspan="1" rowspan="1">20 (10.0)</td><td align="left" colspan="1" rowspan="1">0.864</td></tr><tr><td align="left" colspan="1" rowspan="1">ACEi/ARB, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">25 (12.5)</td><td align="left" colspan="1" rowspan="1">22 (11.0)</td><td align="left" colspan="1" rowspan="1">0.756</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: <italic toggle="yes">PWO</italic> patient with obesity, <italic toggle="yes">PLKD</italic> potential living kidney donors, <italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">HDL</italic> high-density lipoprotein, <italic toggle="yes">LDL</italic> low-density lipoprotein, <italic toggle="yes">ACEi</italic> angiotensin converting enzyme inhibitors, <italic toggle="yes">ARB</italic> angiotensin receptor blockers</p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Kidney function variables in each study group. Results are presented as mean&#8201;&#177;&#8201;standard deviation (SD)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">PWO</th><th align="left" colspan="1" rowspan="1">PLKD</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Serum creatinine (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.76&#8201;&#177;&#8201;0.13</td><td align="left" colspan="1" rowspan="1">0.72&#8201;&#177;&#8201;0.15</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">Proteinuria (mg/day)</td><td align="left" colspan="1" rowspan="1">139.82&#8201;&#177;&#8201;353.26</td><td align="left" colspan="1" rowspan="1">136.35&#8201;&#177;&#8201;62.24</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">Proteinuria&#8201;&#8805;&#8201;150&#160;mg/day, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">44 (22)</td><td align="left" colspan="1" rowspan="1">77 (38.5)</td><td align="left" colspan="1" rowspan="1">0.0005</td></tr><tr><td align="left" colspan="1" rowspan="1">CrCl/BSA (mL/min)</td><td align="left" colspan="1" rowspan="1">115.25&#8201;&#177;&#8201;33.63</td><td align="left" colspan="1" rowspan="1">135.47&#8201;&#177;&#8201;35.56</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">CrCl/BSA&#8201;&#8805;&#8201;140&#160;mL/min, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">41 (20.5)</td><td align="left" colspan="1" rowspan="1">75 (37.5)</td><td align="left" colspan="1" rowspan="1">0.0003</td></tr><tr><td align="left" colspan="1" rowspan="1">CrCl (mL/min)</td><td align="left" colspan="1" rowspan="1">143.35&#8201;&#177;&#8201;45.50</td><td align="left" colspan="1" rowspan="1">133.99&#8201;&#177;&#8201;39.06</td><td align="left" colspan="1" rowspan="1">0.0305</td></tr><tr><td align="left" colspan="1" rowspan="1">ClCr&#8201;&#8805;&#8201;140&#160;mL/min, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">99 (49.5)</td><td align="left" colspan="1" rowspan="1">78 (39)</td><td align="left" colspan="1" rowspan="1">0.0439</td></tr><tr><td align="left" colspan="1" rowspan="1">eGFR (mL/min/1.73 m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">105.43&#8201;&#177;&#8201;14.09</td><td align="left" colspan="1" rowspan="1">106.49&#8201;&#177;&#8201;13.63</td><td align="left" colspan="1" rowspan="1">0.2844</td></tr><tr><td align="left" colspan="1" rowspan="1">eGFR&#8201;&#8805;&#8201;100&#160;mL/min/1.73 m<sup>2</sup>, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">138 (69)</td><td align="left" colspan="1" rowspan="1">149 (74.5)</td><td align="left" colspan="1" rowspan="1">0.267</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: <italic toggle="yes">PWO</italic> patient with obesity, <italic toggle="yes">PLKD</italic> potential living kidney donors, <italic toggle="yes">CrCl</italic> creatinine clearance, <italic toggle="yes">BSA</italic> body surface area, <italic toggle="yes">eGFR</italic> estimated glomerular filtration rate</p></table-wrap-foot></table-wrap></p><p id="Par19">Average serum creatinine was not significantly different between groups. Creatinine clearance was higher than 140&#160;mL/min in 99 patients (49.5%) in the group of PWO and only in 78 patients (39%) in the group of PLKD (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Adjustment of creatinine clearance to BSA underestimated hyperfiltration in the PWO group. Estimation of glomerular filtration rate (eGFR) using CKD-EPI 2021 Creatinine mitigated the differences between groups and resulted in average values that were no longer significantly different between groups, with no patient showing eGFR higher than 140&#160;mL/min/1.73 m<sup>2</sup> in either of the groups (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par20">Although average proteinuria levels were higher in PWO, 38.5% of PLKD presented proteinuria higher than 150&#160;mg/day. This difference was made more evident after filtering for patients with proteinuria higher than 150&#160;mg/day, which the average proteinuria was higher in PWO (329.58&#8201;&#177;&#8201;719.65&#160;mg/day vs 199.18&#8201;&#177;&#8201;50.74&#160;mg/day in PLKD). Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> shows the distribution of patients according to proteinuria and creatinine clearance not corrected for BSA, documenting that for lower levels of creatinine clearance, in PLKD, there is a pattern of proteinuria that ranges within mild figures, while in PWO, higher proteinuria levels are linked to higher creatinine clearance levels.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Distribution of patients according to the level of proteinuria and creatinine clearance (red circles, PWO; blue circles, PLKD)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="11695_2024_7602_Fig1_HTML.jpg"/></fig></p><p id="Par21">Logistic regression using proteinuria either as a continuous variable (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>) or as a categoric variable (higher or lower than 150&#160;mg/day) (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>) showed that creatinine clearance had a significant impact on proteinuria in PWO (HR 1.522, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 and HR 1.014, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, respectively). In PLKD, creatinine clearance also showed to impact proteinuria as a continuous variable, but with a lower strength (HR 0.376, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>), and as a categoric variable (higher or lower than 150&#160;mg/day) (HR 1.015, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>).
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Univariate analysis using proteinuria as a continuous variable as an outcome</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="3" rowspan="1">Proteinuria</th></tr><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="1" rowspan="1">Univariate</th><th align="left" rowspan="2" colspan="1"><italic toggle="yes">p</italic>-value</th></tr><tr><th align="left" colspan="1" rowspan="1">HR (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1"><bold>PLKD</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Uric acid (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;5.653 (&#8722;&#8201;13.640 to 2,334)</td><td align="left" colspan="1" rowspan="1">0.164</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Hemoglobin (g/dL)</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;3.800 (&#8722;&#8201;11.316 to 3.716)</td><td align="left" colspan="1" rowspan="1">0.320</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Glucose (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.434 (&#8722;&#8201;1.328 to 0.461)</td><td align="left" colspan="1" rowspan="1">0.340</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Total cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.006 (&#8722;&#8201;0.228 to 0.241)</td><td align="left" colspan="1" rowspan="1">0.959</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Triglycerides (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.061 (&#8722;&#8201;0.237 to 0.115)</td><td align="left" colspan="1" rowspan="1">0.496</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; HDL cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.098 (&#8722;&#8201;0.729 to 0.533)</td><td align="left" colspan="1" rowspan="1">0.760</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; LDL cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.118 (&#8722;&#8201;0.200 to 0.436)</td><td align="left" colspan="1" rowspan="1">0.465</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Serum creatinine (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;20.217 (&#8722;&#8201;76.885 to 36.451)</td><td align="left" colspan="1" rowspan="1">0.483</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Age (years)</td><td align="left" colspan="1" rowspan="1">0.033 (&#8722;&#8201;0.824 to 0.890)</td><td align="left" colspan="1" rowspan="1">0.940</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; BMI (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">1.746 (&#8722;&#8201;0.869 to 4.361)</td><td align="left" colspan="1" rowspan="1">0.190</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; CrCl/BSA (mL/min)</td><td align="left" colspan="1" rowspan="1">0.377 (0.138&#8211;0.617)</td><td align="left" colspan="1" rowspan="1"><bold>0.002</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; CrCl (mL/min)</td><td align="left" colspan="1" rowspan="1">0.376 (0.159&#8211;0.593)</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; eGFR (mL/min/1.73 m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">0.077 (&#8722;&#8201;0.563 to 0.717)</td><td align="left" colspan="1" rowspan="1">0.812</td></tr><tr><td align="left" colspan="3" rowspan="1"><bold>PWO</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Uric acid (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;6.143 (&#8722;&#8201;43.726 to 31.440)</td><td align="left" colspan="1" rowspan="1">0.748</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Hemoglobin (g/dL)</td><td align="left" colspan="1" rowspan="1">4.621 (&#8722;&#8201;38.390 to 47.632)</td><td align="left" colspan="1" rowspan="1">0.832</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Glucose (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;1.197 (&#8722;&#8201;5.442 to 3.048)</td><td align="left" colspan="1" rowspan="1">0.579</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Total cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.078 (&#8722;&#8201;1.294 to 1.451)</td><td align="left" colspan="1" rowspan="1">0.910</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Triglycerides (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.013 (&#8722;&#8201;0.783 to 0.809)</td><td align="left" colspan="1" rowspan="1">0.974</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; HDL cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.191 (&#8722;&#8201;4.348 to 4.729)</td><td align="left" colspan="1" rowspan="1">0.934</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; LDL cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.217 (&#8722;&#8201;1.150 to 1.583)</td><td align="left" colspan="1" rowspan="1">0.755</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Serum creatinine (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;205.075 (&#8722;&#8201;585.053 to 174.903)</td><td align="left" colspan="1" rowspan="1">0.288</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Age (years)</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;2.816 (&#8722;&#8201;7.139 to 1.507)</td><td align="left" colspan="1" rowspan="1">0.200</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; BMI (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">2.645 (&#8722;&#8201;6.654 to 11.944)</td><td align="left" colspan="1" rowspan="1">0.575</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; CrCl/BSA (mL/min)</td><td align="left" colspan="1" rowspan="1">1.887 (0.439&#8211;3.335)</td><td align="left" colspan="1" rowspan="1"><bold>0.011</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; CrCl (mL/min)</td><td align="left" colspan="1" rowspan="1">1.522 (0.455&#8211;2.589)</td><td align="left" colspan="1" rowspan="1"><bold>0.005</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; eGFR (mL/min/1.73 m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">3.112 (&#8722;&#8201;0.376 to 6.599)</td><td align="left" colspan="1" rowspan="1">0.080</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: <italic toggle="yes">PWO</italic> patient with obesity, <italic toggle="yes">PLKD</italic> potential living kidney donors, <italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">HDL</italic> high-density lipoprotein, <italic toggle="yes">LDL</italic> low-density lipoprotein, <italic toggle="yes">CrCl</italic> creatinine clearance, <italic toggle="yes">BSA</italic> body surface area, <italic toggle="yes">eGFR</italic> estimated glomerular filtration rate</p><p>Data in bold emphasis indicates a statistically significant p-value</p></table-wrap-foot></table-wrap><table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Univariate and multivariate analysis using proteinuria as a categoric variable (higher or lower than 140&#160;mL/min) as an outcome</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Univariate</th><th align="left" colspan="2" rowspan="1">Multivariate</th></tr><tr><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1"><bold>PLKD</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Uric acid (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.795 (0.596&#8211;1.060)</td><td align="left" colspan="1" rowspan="1">0.795</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Hemoglobin (g/dL)</td><td align="left" colspan="1" rowspan="1">0.898 (0.700&#8211;1.151)</td><td align="left" colspan="1" rowspan="1">0.396</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Glucose (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.977 (0.945&#8211;1.010)</td><td align="left" colspan="1" rowspan="1">0.167</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Total cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.999 (0.992&#8211;1.007)</td><td align="left" colspan="1" rowspan="1">0.885</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Triglycerides (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.997 (0.991&#8211;1.003)</td><td align="left" colspan="1" rowspan="1">0.437</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; HDL cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">1.005 (0.985&#8211;1.026)</td><td align="left" colspan="1" rowspan="1">0.635</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; LDL cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">1.002 (0.992&#8211;1.012)</td><td align="left" colspan="1" rowspan="1">0.703</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">&#160; Serum creatinine (mg/dL)</td><td align="left" rowspan="2" colspan="1">0.139 (0.020&#8211;0.984)</td><td align="left" rowspan="2" colspan="1"><bold>0.048</bold></td><td align="left" colspan="1" rowspan="1">0.294 (0.038&#8211;2.260)<sup>$</sup></td><td align="left" colspan="1" rowspan="1">0.294<sup>$</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">0.199 (0.027&#8211;1.465)<sup>#</sup></td><td align="left" colspan="1" rowspan="1">0.133<sup>#</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Age (years)</td><td align="left" colspan="1" rowspan="1">0.998 (0.971&#8211;1.027)</td><td align="left" colspan="1" rowspan="1">0.898</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; BMI (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">1.066 (0.978&#8211;1.163)</td><td align="left" colspan="1" rowspan="1">0.144</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; CrCl/BSA (mL/min)</td><td align="left" colspan="1" rowspan="1">1.014 (1.005&#8211;1.023)</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td><td align="left" colspan="1" rowspan="1">1.013 (1.004&#8211;1.022)<sup>&#167;</sup></td><td align="left" colspan="1" rowspan="1"><bold>0.005</bold><sup>&#167;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; CrCl (mL/min)</td><td align="left" colspan="1" rowspan="1">1.015 (1.007&#8211;1.024)</td><td align="left" colspan="1" rowspan="1"><bold>0.000</bold></td><td align="left" colspan="1" rowspan="1">1.015 (1.006&#8211;1.023)<sup>&#167;</sup></td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold><sup>&#167;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; eGFR (mL/min/1.73 m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">1.011 (0.990&#8211;1.033)</td><td align="left" colspan="1" rowspan="1">0.313</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="5" rowspan="1"><bold>PWO</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Uric acid (mg/dL)</td><td align="left" colspan="1" rowspan="1">1.186 (0.925&#8211;1.522)</td><td align="left" colspan="1" rowspan="1">0.179</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Hemoglobin (g/dL)</td><td align="left" colspan="1" rowspan="1">1.228 (0.921&#8211;1.637)</td><td align="left" colspan="1" rowspan="1">0.162</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Glucose (mg/dL)</td><td align="left" colspan="1" rowspan="1">1.014 (0.986&#8211;1.042)</td><td align="left" colspan="1" rowspan="1">0.340</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Total cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">1.002 (0.993&#8211;1.011)</td><td align="left" colspan="1" rowspan="1">0.657</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Triglycerides (mg/dL)</td><td align="left" colspan="1" rowspan="1">1.003 (0.998&#8211;1.009)</td><td align="left" colspan="1" rowspan="1">0.185</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; HDL cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.973 (0.941&#8211;1.006)</td><td align="left" colspan="1" rowspan="1">0.104</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; LDL cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">1.002 (0.993&#8211;1.011)</td><td align="left" colspan="1" rowspan="1">0.646</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Serum creatinine (mg/dL)</td><td align="left" colspan="1" rowspan="1">2.651 (0.242&#8211;28.997)</td><td align="left" colspan="1" rowspan="1">0.424</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; Age (years)</td><td align="left" colspan="1" rowspan="1">1.003 (0.974&#8211;1.033)</td><td align="left" colspan="1" rowspan="1">0.821</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; BMI (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">1.025 (0.965&#8211;1.089)</td><td align="left" colspan="1" rowspan="1">0.417</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; CrCl/BSA (mL/min)</td><td align="left" colspan="1" rowspan="1">1.019 (1.008&#8211;1.031)</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; CrCl (mL/min)</td><td align="left" colspan="1" rowspan="1">1.014 (1.006&#8211;1.022)</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160; eGFR (mL/min/1.73 m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">1.011 (0.986&#8211;1.036)</td><td align="left" colspan="1" rowspan="1">0.404</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><sup>$</sup>Adjusted to CrCl/BSA values</p><p><sup>#</sup>Adjusted to CrCl levels</p><p>&#167;Adjusted to serum creatinine levels</p><p>Abbreviations: <italic toggle="yes">PWO</italic> patient with obesity, <italic toggle="yes">PLKD</italic> potential living kidney donors, <italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">HDL</italic> high-density lipoprotein, <italic toggle="yes">LDL</italic> low-density lipoprotein, <italic toggle="yes">CrCl</italic> creatinine clearance, <italic toggle="yes">BSA</italic> body surface area, <italic toggle="yes">eGFR</italic> estimated glomerular filtration rate</p><p>Data in bold emphasis indicates a statistically significant p-value</p></table-wrap-foot></table-wrap></p><p id="Par22">ROC analysis showed creatinine clearance adjusted and unadjusted for BSA had a significant predictive capacity for proteinuria (AUC 0.630, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 and AUC 0.660, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, respectively), while BMI was not predictive for proteinuria level.</p></sec><sec id="Sec8"><title>Discussion</title><p id="Par23">In this work, we sought to identify the biomarkers that characterize obesity-related kidney disease. For this, we compared a group of PWO candidates for bariatric surgery with a group of PLKD candidates without obesity, expectedly devoid of clinically relevant health conditions known to impact kidney function, and therefore used as a control.</p><p id="Par24">Important methodological issues were considered. Firstly, patients were matched according to age and sex, two variables that are known to have a significant impact in glomerular filtration rate and proteinuria levels [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Moreover, there are significant differences in body composition inherent to age and sex [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], to which this pair-matching also answers. Secondly, measurements were based on a 24-h urine collection. Creatinine clearance was evaluated with and without indexing for BSA, to ascertain the impact of the systematic underestimation of glomerular filtration rate (GFR) that happens with BSA indexing, which affects particularly patients with obesity [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Finally, the fact that patients with diabetes or any inflammatory disease were excluded from the study allowed us to reduce the chances of bias due to potential kidney alterations associated not with obesity but with diabetic kidney disease or inflammatory etiologies.</p><p id="Par25">The proportion of individuals with creatinine clearance greater than 140&#160;mL/min and average creatinine clearance were significantly higher in PWO compared to PLKD. Unsurprisingly,&#160;since obesity is characterized by increased renal plasma flow, glomerular filtration rate, and filtration fraction [<xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>]. Noticeably, indexing creatinine clearance for BSA inverted these results: the proportion of patients with filtration rates greater than 140&#160;mL/min was lower in PWO compared to PLKD and average creatinine clearance corrected for BSA was lower in PWO. Measurements of GFR such as creatinine clearance are commonly corrected for BSA to account for differences in body size. However, in PWO, this has shown to lead to a systematic underestimation of GFR [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], because GFR does not increase in parallel to adiposity, but is rather a result of single nephron filtration increase [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. The higher the BMIs the more significant the masking effect of indexing creatinine clearance for BSA, resulting in a misleading creatinine clearance value, lower in PWO. Therefore, our study further reinforces the need to abandon the use of eGFR calculations that use standardization for BSA in the setting of obesity. Differences between measured creatinine clearance and eGFR calculated using CKD-EPI-Creatinine 2021 also became apparent in our study. Average values of eGFR were significantly below the value of measured creatinine clearance for both groups, mitigating the differences between groups. The CKD-EPI Creatinine equation is based on sex, age, and serum creatinine and has been shown to significantly overestimate the presence of chronic kidney disease and underestimate the rate of hyperfiltration in the population with obesity [<xref ref-type="bibr" rid="CR36">36</xref>]. This has motivated to attempts to the development of new eGFR equation models to be specifically applied in PWO [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par26">Average proteinuria was also significantly higher among PWO, a difference which was even more striking when only proteinuria greater than 150&#160;mg/day was considered. Proteinuria is a characteristic feature of obesity-related glomerulopathy [<xref ref-type="bibr" rid="CR2">2</xref>]. Additionally, adiposity was shown to correlate with protein excretion [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Indeed, in a recent cross-sectional study with more than 400,000 people from the UK Biobank, for each BMI increment of 5&#160;kg/m<sup>2</sup>, the odds of a higher albuminuria category were 47% greater [<xref ref-type="bibr" rid="CR40">40</xref>]. Unexpectedly, although the magnitude proteinuria was lower, the number of individuals with clinically significant proteinuria was greater in PLKD (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Although this is not quite surprising, since low levels of proteinuria may be acceptable in PLDK, kidney donation in the presence of borderline medical abnormalities is being increasingly accepted [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref>]. Several factors have been appointed as the culprits for proteinuria in PWO [<xref ref-type="bibr" rid="CR44">44</xref>]. One of the major determinants shown to impact on proteinuria is hyperfiltration [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Our logistic regression model showed that creatinine clearance positively impacted on the levels of proteinuria in PWO, but to a lower extent in PLKD (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). This effect was observed even when creatinine clearance was corrected for BSA in both groups. This is a significant finding, as it suggests that in PWO hyperfiltration is disproportionately detrimental to the glomerular barrier, translating in greater proteinuria as compared to individuals of the control group with similar hyperfiltration, suggesting that in the presence of obesity, the mechanisms leading to proteinuria might differ. Thus, obesity may favor pathophysiological pathways that translate into glomerular protein loss in the setting of hyperfiltration. Indeed, besides modifying glomerular hemodynamics, several other obesity-specific kidney lesion pathways have been described [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. A detailed evaluation of the albumin-to-protein ratio [<xref ref-type="bibr" rid="CR49">49</xref>&#8211;<xref ref-type="bibr" rid="CR51">51</xref>] and proteomic analysis could be valuable to distinguish between glomerular versus tubular proteinuria and differentiate lesion pathways[<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par27">Of particular notice, neither cholesterol nor serum uric acid was shown to significantly affect proteinuria in any of the groups, in contrast to what other authors have shown [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>],</p><p id="Par28">This study harbors some limitations to acknowledge. The cross-sectional nature of our study is an inherent limitation. The analysis would be greatly enriched with follow-up of these patients, possibly providing new insights about particularities in the pathophysiology of obesity-related kidney disease. Additionally, measurements of albuminuria and other urinary proteins could be valuable to better characterize kidney dysfunction and evaluate specific pathways of the lesion. Notwithstanding, our study has several important strengths. The fact that we used propensity analysis to minimize differences in baseline characteristics between both groups and had access to a large number of patients allowed us enough power to depict robust statistical differences. Furthermore, we evaluated kidney function using a 24-h urine collection and analyzed creatinine clearance using indexed and non-indexed values.</p><p id="Par29">In conclusion, glomerular hyperfiltration and disproportionate proteinuria are the hallmarks of obesity-related kidney dysfunction. Given the prevalence of kidney disorders and the challenges of kidney function assessment in obesity, our study suggests that proteinuria should be routinely evaluated in bariatric surgery candidates.</p></sec></body><back><fn-group><fn><p><bold>Key Points</bold></p><p>&#8226; Hyperfiltration and disproportionate proteinuria are frequent in bariatric surgery candidates.</p><p>&#8226; Creatinine clearance calculations indexed for body surface area can mask hyperfiltration in patients with obesity.</p><p>&#8226; Appropriate markers are needed to detect obesity-related kidney disease in bariatric surgery candidates.</p></fn><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contribution</title><p>PRP, MPM, and AR planned and designed the study. PRP, MA, JP, MG, JM, LSM, and MN conducted data acquisition. PRP, PB, and SSP performed the statistical analysis. PRP, MPM, and AR participated in data analysis and interpretation. PRP wrote the manuscript. PRP, MPM, PB, SSP, JM, MA, LSM, MN, MG, and AR reviewed the manuscript. All the authors approved the submitted version. PRP is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by FCT|FCCN (b-on). This research was funded by Funda&#231;&#227;o para a Ci&#234;ncia e a Tecnologia by the following grants: UIDB/00215/2020, UIDP/00215/2020, LA/P/0064/2020 and UI/BD/150750/2020.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par30">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yau</surname><given-names>K</given-names></name><name name-style="western"><surname>Kuah</surname><given-names>R</given-names></name><name name-style="western"><surname>Cherney</surname><given-names>DZI</given-names></name><name name-style="western"><surname>Lam</surname><given-names>TKT</given-names></name></person-group><article-title>Obesity and the kidney: mechanistic links and therapeutic advances</article-title><source>Nat Rev Endocrinol.</source><year>2024</year><volume>20</volume><issue>6</issue><fpage>321</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1038/s41574-024-00951-7</pub-id><pub-id pub-id-type="pmid">38351406</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Yau K, Kuah R, Cherney DZI, Lam TKT. Obesity and the kidney: mechanistic links and therapeutic advances. Nat Rev Endocrinol. 2024;20(6):321&#8211;35. 10.1038/s41574-024-00951-7.<pub-id pub-id-type="pmid">38351406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-024-00951-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Agati</surname><given-names>VD</given-names></name><name name-style="western"><surname>Chagnac</surname><given-names>A</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis</article-title><source>Nat Rev Nephrol</source><year>2016</year><volume>12</volume><issue>8</issue><fpage>453</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2016.75</pub-id><pub-id pub-id-type="pmid">27263398</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">D&#8217;Agati VD, Chagnac A, de Vries AP, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016;12(8):453&#8211;71.<pub-id pub-id-type="pmid">27263398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneph.2016.75</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonnet</surname><given-names>F</given-names></name><name name-style="western"><surname>Deprele</surname><given-names>C</given-names></name><name name-style="western"><surname>Sassolas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis</article-title><source>Am J Kidney Dis</source><year>2001</year><volume>37</volume><issue>4</issue><fpage>720</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(01)80120-7</pub-id><pub-id pub-id-type="pmid">11273871</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis. 2001;37(4):720&#8211;7.<pub-id pub-id-type="pmid">11273871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0272-6386(01)80120-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffin</surname><given-names>KA</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>H</given-names></name><name name-style="western"><surname>Bidani</surname><given-names>AK</given-names></name></person-group><article-title>Adverse renal consequences of obesity</article-title><source>Am J Physiol Renal Physiol</source><year>2008</year><volume>294</volume><issue>4</issue><fpage>F685</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00324.2007</pub-id><pub-id pub-id-type="pmid">18234955</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol. 2008;294(4):F685-696.<pub-id pub-id-type="pmid">18234955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajprenal.00324.2007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strazzullo</surname><given-names>P</given-names></name><name name-style="western"><surname>Barba</surname><given-names>G</given-names></name><name name-style="western"><surname>Cappuccio</surname><given-names>FP</given-names></name><etal/></person-group><article-title>Altered renal sodium handling in men with abdominal adiposity: a link to hypertension</article-title><source>J Hypertens</source><year>2001</year><volume>19</volume><issue>12</issue><fpage>2157</fpage><lpage>2164</lpage><pub-id pub-id-type="doi">10.1097/00004872-200112000-00007</pub-id><pub-id pub-id-type="pmid">11725158</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Strazzullo P, Barba G, Cappuccio FP, et al. Altered renal sodium handling in men with abdominal adiposity: a link to hypertension. J Hypertens. 2001;19(12):2157&#8211;64.<pub-id pub-id-type="pmid">11725158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00004872-200112000-00007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engeli</surname><given-names>S</given-names></name><name name-style="western"><surname>B&#246;hnke</surname><given-names>J</given-names></name><name name-style="western"><surname>Gorzelniak</surname><given-names>K</given-names></name><etal/></person-group><article-title>Weight loss and the renin-angiotensin-aldosterone system</article-title><source>Hypertension</source><year>2005</year><volume>45</volume><issue>3</issue><fpage>356</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000154361.47683.d3</pub-id><pub-id pub-id-type="pmid">15630041</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Engeli S, B&#246;hnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356&#8211;62.<pub-id pub-id-type="pmid">15630041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.HYP.0000154361.47683.d3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsuboi</surname><given-names>N</given-names></name><name name-style="western"><surname>Okabayashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>A</given-names></name><etal/></person-group><article-title>The renal pathology of obesity</article-title><source>Kidney Int Rep</source><year>2017</year><volume>2</volume><issue>2</issue><fpage>251</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.ekir.2017.01.007</pub-id><pub-id pub-id-type="pmid">29142961</pub-id><pub-id pub-id-type="pmcid">PMC5678647</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Tsuboi N, Okabayashi Y, Shimizu A, et al. The renal pathology of obesity. Kidney Int Rep. 2017;2(2):251&#8211;60.<pub-id pub-id-type="pmid">29142961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ekir.2017.01.007</pub-id><pub-id pub-id-type="pmcid">PMC5678647</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vries</surname><given-names>AP</given-names></name><name name-style="western"><surname>Ruggenenti</surname><given-names>P</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>XZ</given-names></name><etal/></person-group><article-title>Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease</article-title><source>Lancet Diabetes Endocrinol</source><year>2014</year><volume>2</volume><issue>5</issue><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(14)70065-8</pub-id><pub-id pub-id-type="pmid">24795255</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">de Vries AP, Ruggenenti P, Ruan XZ, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417&#8211;26.<pub-id pub-id-type="pmid">24795255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(14)70065-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Parker</surname><given-names>JL</given-names></name><name name-style="western"><surname>Lugus</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Adipokines in inflammation and metabolic disease</article-title><source>Nat Rev Immunol</source><year>2011</year><volume>11</volume><issue>2</issue><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1038/nri2921</pub-id><pub-id pub-id-type="pmid">21252989</pub-id><pub-id pub-id-type="pmcid">PMC3518031</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85&#8211;97.<pub-id pub-id-type="pmid">21252989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2921</pub-id><pub-id pub-id-type="pmcid">PMC3518031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Virtue</surname><given-names>S</given-names></name><name name-style="western"><surname>Vidal-Puig</surname><given-names>A</given-names></name></person-group><article-title>Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome&#8211;an allostatic perspective</article-title><source>Biochim Biophys Acta</source><year>2010</year><volume>1801</volume><issue>3</issue><fpage>338</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2009.12.006</pub-id><pub-id pub-id-type="pmid">20056169</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome&#8211;an allostatic perspective. Biochim Biophys Acta. 2010;1801(3):338&#8211;49.<pub-id pub-id-type="pmid">20056169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbalip.2009.12.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>N</given-names></name><name name-style="western"><surname>Hertig</surname><given-names>A</given-names></name></person-group><article-title>Alteration of fatty acid oxidation in tubular epithelial cells: from acute kidney injury to renal fibrogenesis</article-title><source>Front Med (Lausanne)</source><year>2015</year><volume>2</volume><fpage>52</fpage><pub-id pub-id-type="pmid">26301223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2015.00052</pub-id><pub-id pub-id-type="pmcid">PMC4525064</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Simon N, Hertig A. Alteration of fatty acid oxidation in tubular epithelial cells: from acute kidney injury to renal fibrogenesis. Front Med (Lausanne). 2015;2:52.<pub-id pub-id-type="pmid">26301223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2015.00052</pub-id><pub-id pub-id-type="pmcid">PMC4525064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deb</surname><given-names>DK</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X</given-names></name><etal/></person-group><article-title>ATP-citrate lyase is an epigenetic regulator to promote obesity-related kidney injury</article-title><source>Faseb J</source><year>2019</year><volume>33</volume><issue>8</issue><fpage>9602</fpage><lpage>9615</lpage><pub-id pub-id-type="doi">10.1096/fj.201900213R</pub-id><pub-id pub-id-type="pmid">31150280</pub-id><pub-id pub-id-type="pmcid">PMC6662982</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Chen Y, Deb DK, Fu X, et al. ATP-citrate lyase is an epigenetic regulator to promote obesity-related kidney injury. Faseb J. 2019;33(8):9602&#8211;15.<pub-id pub-id-type="pmid">31150280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201900213R</pub-id><pub-id pub-id-type="pmcid">PMC6662982</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Proctor</surname><given-names>G</given-names></name><etal/></person-group><article-title>Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><issue>37</issue><fpage>32317</fpage><lpage>32325</lpage><pub-id pub-id-type="doi">10.1074/jbc.M500801200</pub-id><pub-id pub-id-type="pmid">16046411</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Jiang T, Wang Z, Proctor G, et al. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem. 2005;280(37):32317&#8211;25.<pub-id pub-id-type="pmid">16046411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M500801200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorotea</surname><given-names>D</given-names></name><name name-style="western"><surname>Koya</surname><given-names>D</given-names></name><name name-style="western"><surname>Ha</surname><given-names>H</given-names></name></person-group><article-title>Recent insights Into SREBP as a direct mediator of kidney fibrosis via lipid-independent pathways</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>265</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00265</pub-id><pub-id pub-id-type="pmid">32256356</pub-id><pub-id pub-id-type="pmcid">PMC7092724</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Dorotea D, Koya D, Ha H. Recent insights Into SREBP as a direct mediator of kidney fibrosis via lipid-independent pathways. Front Pharmacol. 2020;11:265.<pub-id pub-id-type="pmid">32256356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.00265</pub-id><pub-id pub-id-type="pmcid">PMC7092724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>PE</given-names></name></person-group><article-title>Immunologic and endocrine functions of adipose tissue: implications for kidney disease</article-title><source>Nat Rev Nephrol</source><year>2018</year><volume>14</volume><issue>2</issue><fpage>105</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2017.157</pub-id><pub-id pub-id-type="pmid">29199276</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhu Q, Scherer PE. Immunologic and endocrine functions of adipose tissue: implications for kidney disease. Nat Rev Nephrol. 2018;14(2):105&#8211;20.<pub-id pub-id-type="pmid">29199276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneph.2017.157</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>TY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>RF</given-names></name><name name-style="western"><surname>Bu</surname><given-names>ZY</given-names></name><etal/></person-group><article-title>Association of metabolic dysfunction-associated fatty liver disease with kidney disease</article-title><source>Nat Rev Nephrol</source><year>2022</year><volume>18</volume><issue>4</issue><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1038/s41581-021-00519-y</pub-id><pub-id pub-id-type="pmid">35013596</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wang TY, Wang RF, Bu ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18(4):259&#8211;68.<pub-id pub-id-type="pmid">35013596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-021-00519-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cachat</surname><given-names>F</given-names></name><name name-style="western"><surname>Combescure</surname><given-names>C</given-names></name><name name-style="western"><surname>Cauderay</surname><given-names>M</given-names></name><etal/></person-group><article-title>A systematic review of glomerular hyperfiltration assessment and definition in the medical literature</article-title><source>Clin J Am Soc Nephrol</source><year>2015</year><volume>10</volume><issue>3</issue><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.2215/CJN.03080314</pub-id><pub-id pub-id-type="pmid">25568216</pub-id><pub-id pub-id-type="pmcid">PMC4348676</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Cachat F, Combescure C, Cauderay M, et al. A systematic review of glomerular hyperfiltration assessment and definition in the medical literature. Clin J Am Soc Nephrol. 2015;10(3):382&#8211;9.<pub-id pub-id-type="pmid">25568216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.03080314</pub-id><pub-id pub-id-type="pmcid">PMC4348676</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delanaye</surname><given-names>P</given-names></name><name name-style="western"><surname>Mariat</surname><given-names>C</given-names></name><name name-style="western"><surname>Cavalier</surname><given-names>E</given-names></name><etal/></person-group><article-title>Errors induced by indexing glomerular filtration rate for body surface area: reductio ad absurdum</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><issue>12</issue><fpage>3593</fpage><lpage>3596</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfp431</pub-id><pub-id pub-id-type="pmid">19734136</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Delanaye P, Mariat C, Cavalier E, et al. Errors induced by indexing glomerular filtration rate for body surface area: reductio ad absurdum. Nephrol Dial Transplant. 2009;24(12):3593&#8211;6.<pub-id pub-id-type="pmid">19734136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfp431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez-Mart&#237;nez</surname><given-names>M</given-names></name><name name-style="western"><surname>Luis-Lima</surname><given-names>S</given-names></name><name name-style="western"><surname>Morales</surname><given-names>E</given-names></name><etal/></person-group><article-title>The estimation of GFR and the adjustment for BSA in overweight and obesity: a dreadful combination of two errors</article-title><source>Int J Obes (Lond)</source><year>2020</year><volume>44</volume><issue>5</issue><fpage>1129</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1038/s41366-019-0476-z</pub-id><pub-id pub-id-type="pmid">31641213</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">L&#243;pez-Mart&#237;nez M, Luis-Lima S, Morales E, et al. The estimation of GFR and the adjustment for BSA in overweight and obesity: a dreadful combination of two errors. Int J Obes (Lond). 2020;44(5):1129&#8211;40.<pub-id pub-id-type="pmid">31641213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41366-019-0476-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reese</surname><given-names>PP</given-names></name><name name-style="western"><surname>Boudville</surname><given-names>N</given-names></name><name name-style="western"><surname>Garg</surname><given-names>AX</given-names></name></person-group><article-title>Living kidney donation: outcomes, ethics, and uncertainty</article-title><source>Lancet</source><year>2015</year><volume>385</volume><issue>9981</issue><fpage>2003</fpage><lpage>2013</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)62484-3</pub-id><pub-id pub-id-type="pmid">26090646</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Reese PP, Boudville N, Garg AX. Living kidney donation: outcomes, ethics, and uncertainty. Lancet. 2015;385(9981):2003&#8211;13.<pub-id pub-id-type="pmid">26090646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(14)62484-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>M</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>C</given-names></name><name name-style="western"><surname>Silvano</surname><given-names>J</given-names></name><name name-style="western"><surname>Pedroso</surname><given-names>S</given-names></name><name name-style="western"><surname>Tafulo</surname><given-names>S</given-names></name><name name-style="western"><surname>Martins</surname><given-names>S</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>M</given-names></name><name name-style="western"><surname>Malheiro</surname><given-names>J</given-names></name></person-group><article-title>Living donors' age modifies the impact of pre-donation estimated glomerular filtration rate on graft survival</article-title><source>J Clin Med.</source><year>2023</year><volume>12</volume><issue>21</issue><fpage>6777</fpage><pub-id pub-id-type="doi">10.3390/jcm12216777</pub-id><pub-id pub-id-type="pmid">37959241</pub-id><pub-id pub-id-type="pmcid">PMC10649187</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Almeida M, Ribeiro C, Silvano J, Pedroso S, Tafulo S, Martins S, Ramos M, Malheiro J. Living donors&#8217; age modifies the impact of pre-donation estimated glomerular filtration rate on graft survival. J Clin Med. 2023;12(21):6777. 10.3390/jcm12216777.<pub-id pub-id-type="pmid">37959241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12216777</pub-id><pub-id pub-id-type="pmcid">PMC10649187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>LA</given-names></name><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name></person-group><article-title>Measured GFR as a confirmatory test for estimated GFR</article-title><source>J Am Soc Nephrol</source><year>2009</year><volume>20</volume><issue>11</issue><fpage>2305</fpage><lpage>2313</lpage><pub-id pub-id-type="doi">10.1681/ASN.2009020171</pub-id><pub-id pub-id-type="pmid">19833901</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol. 2009;20(11):2305&#8211;13.<pub-id pub-id-type="pmid">19833901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2009020171</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>YH</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Changes in body composition according to age and sex among young non-diabetic Korean adults: the Kangbuk Samsung health study</article-title><source>Endocrinol Metab (Seoul)</source><year>2017</year><volume>32</volume><issue>4</issue><fpage>442</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.3803/EnM.2017.32.4.442</pub-id><pub-id pub-id-type="pmid">29199402</pub-id><pub-id pub-id-type="pmcid">PMC5744730</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Kim SK, Kwon YH, Cho JH, et al. Changes in body composition according to age and sex among young non-diabetic Korean adults: the Kangbuk Samsung health study. Endocrinol Metab (Seoul). 2017;32(4):442&#8211;50.<pub-id pub-id-type="pmid">29199402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3803/EnM.2017.32.4.442</pub-id><pub-id pub-id-type="pmcid">PMC5744730</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lentine</surname><given-names>KL</given-names></name><name name-style="western"><surname>Kasiske</surname><given-names>BL</given-names></name><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Summary of kidney disease: improving global outcomes (KDIGO) clinical practice guideline on the evaluation and care of living kidney donors</article-title><source>Transplantation</source><year>2017</year><volume>101</volume><issue>8</issue><fpage>1783</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000001770</pub-id><pub-id pub-id-type="pmid">28737659</pub-id><pub-id pub-id-type="pmcid">PMC5542788</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Lentine KL, Kasiske BL, Levey AS, et al. Summary of kidney disease: improving global outcomes (KDIGO) clinical practice guideline on the evaluation and care of living kidney donors. Transplantation. 2017;101(8):1783&#8211;92.<pub-id pub-id-type="pmid">28737659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TP.0000000000001770</pub-id><pub-id pub-id-type="pmcid">PMC5542788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manas</surname><given-names>D</given-names></name><name name-style="western"><surname>Burnapp</surname><given-names>L</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>PA</given-names></name></person-group><article-title>Summary of the British Transplantation Society UK guidelines for living donor liver transplantation</article-title><source>Transplantation</source><year>2016</year><volume>100</volume><issue>6</issue><fpage>1184</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000001128</pub-id><pub-id pub-id-type="pmid">26950721</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Manas D, Burnapp L, Andrews PA. Summary of the British Transplantation Society UK guidelines for living donor liver transplantation. Transplantation. 2016;100(6):1184&#8211;90.<pub-id pub-id-type="pmid">26950721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TP.0000000000001128</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inker</surname><given-names>LA</given-names></name><name name-style="western"><surname>Eneanya</surname><given-names>ND</given-names></name><name name-style="western"><surname>Coresh</surname><given-names>J</given-names></name><etal/></person-group><article-title>New creatinine- and cystatin c-based equations to estimate GFR without race</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><issue>19</issue><fpage>1737</fpage><lpage>1749</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2102953</pub-id><pub-id pub-id-type="pmid">34554658</pub-id><pub-id pub-id-type="pmcid">PMC8822996</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin c-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737&#8211;49.<pub-id pub-id-type="pmid">34554658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102953</pub-id><pub-id pub-id-type="pmcid">PMC8822996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du Bois</surname><given-names>D</given-names></name><name name-style="western"><surname>Du Bois</surname><given-names>EF</given-names></name></person-group><article-title>A formula to estimate the approximate surface area if height and weight be known. 1916</article-title><source>Nutrition</source><year>1989</year><volume>5</volume><issue>5</issue><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">2520314</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5(5):303&#8211;11 (<bold>discussion 312-303</bold>).<pub-id pub-id-type="pmid">2520314</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>PE</given-names></name><name name-style="western"><surname>Levin</surname><given-names>A</given-names></name></person-group><article-title>Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline</article-title><source>Ann Intern Med</source><year>2013</year><volume>158</volume><issue>11</issue><fpage>825</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-158-11-201306040-00007</pub-id><pub-id pub-id-type="pmid">23732715</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825&#8211;30.<pub-id pub-id-type="pmid">23732715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-158-11-201306040-00007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name><name name-style="western"><surname>Inker</surname><given-names>LA</given-names></name><name name-style="western"><surname>Coresh</surname><given-names>J</given-names></name></person-group><article-title>GFR estimation: from physiology to public health</article-title><source>Am J Kidney Dis</source><year>2014</year><volume>63</volume><issue>5</issue><fpage>820</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2013.12.006</pub-id><pub-id pub-id-type="pmid">24485147</pub-id><pub-id pub-id-type="pmcid">PMC4001724</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014;63(5):820&#8211;34.<pub-id pub-id-type="pmid">24485147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2013.12.006</pub-id><pub-id pub-id-type="pmcid">PMC4001724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karvonen-Gutierrez</surname><given-names>C</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C</given-names></name></person-group><article-title>Association of mid-life changes in body size, body composition and obesity status with the menopausal transition</article-title><source>Healthcare (Basel).</source><year>2016</year><volume>4</volume><issue>3</issue><fpage>42</fpage><pub-id pub-id-type="doi">10.3390/healthcare4030042</pub-id><pub-id pub-id-type="pmid">27417630</pub-id><pub-id pub-id-type="pmcid">PMC5041043</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Karvonen-Gutierrez C, Kim C. Association of mid-life changes in body size, body composition and obesity status with the menopausal transition. Healthcare (Basel). 2016;4(3):42. 10.3390/healthcare4030042.<pub-id pub-id-type="pmid">27417630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/healthcare4030042</pub-id><pub-id pub-id-type="pmcid">PMC5041043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porter</surname><given-names>LE</given-names></name><name name-style="western"><surname>Hollenberg</surname><given-names>NK</given-names></name></person-group><article-title>Obesity, salt intake, and renal perfusion in healthy humans</article-title><source>Hypertension</source><year>1998</year><volume>32</volume><issue>1</issue><fpage>144</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.32.1.144</pub-id><pub-id pub-id-type="pmid">9674651</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Porter LE, Hollenberg NK. Obesity, salt intake, and renal perfusion in healthy humans. Hypertension. 1998;32(1):144&#8211;8.<pub-id pub-id-type="pmid">9674651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.hyp.32.1.144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reisin</surname><given-names>E</given-names></name><name name-style="western"><surname>Messerli</surname><given-names>FG</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>HO</given-names></name><etal/></person-group><article-title>Renal haemodynamic studies in obesity hypertension</article-title><source>J Hypertens</source><year>1987</year><volume>5</volume><issue>4</issue><fpage>397</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1097/00004872-198708000-00002</pub-id><pub-id pub-id-type="pmid">3668243</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Reisin E, Messerli FG, Ventura HO, et al. Renal haemodynamic studies in obesity hypertension. J Hypertens. 1987;5(4):397&#8211;400.<pub-id pub-id-type="pmid">3668243</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chagnac</surname><given-names>A</given-names></name><name name-style="western"><surname>Herman</surname><given-names>M</given-names></name><name name-style="western"><surname>Zingerman</surname><given-names>B</given-names></name><etal/></person-group><article-title>Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption</article-title><source>Nephrol Dial Transplant</source><year>2008</year><volume>23</volume><issue>12</issue><fpage>3946</fpage><lpage>3952</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfn379</pub-id><pub-id pub-id-type="pmid">18622024</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant. 2008;23(12):3946&#8211;52.<pub-id pub-id-type="pmid">18622024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfn379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slone</surname><given-names>TH</given-names></name></person-group><article-title>Body surface area misconceptions</article-title><source>Risk Anal</source><year>1993</year><volume>13</volume><issue>4</issue><fpage>375</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1111/j.1539-6924.1993.tb00736.x</pub-id><pub-id pub-id-type="pmid">8234944</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Slone TH. Body surface area misconceptions. Risk Anal. 1993;13(4):375&#8211;7.<pub-id pub-id-type="pmid">8234944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1539-6924.1993.tb00736.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dooley</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Poole</surname><given-names>SG</given-names></name></person-group><article-title>Poor correlation between body surface area and glomerular filtration rate</article-title><source>Cancer Chemother Pharmacol</source><year>2000</year><volume>46</volume><issue>6</issue><fpage>523</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1007/PL00006751</pub-id><pub-id pub-id-type="pmid">11138467</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Dooley MJ, Poole SG. Poor correlation between body surface area and glomerular filtration rate. Cancer Chemother Pharmacol. 2000;46(6):523&#8211;6.<pub-id pub-id-type="pmid">11138467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/PL00006751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domislovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Domislovic</surname><given-names>V</given-names></name><name name-style="western"><surname>Fucek</surname><given-names>M</given-names></name><etal/></person-group><article-title>Should the CKD EPI equation be used for estimation of the glomerular filtration rate in obese subjects?</article-title><source>Kidney Blood Press Res</source><year>2022</year><volume>47</volume><issue>10</issue><fpage>597</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1159/000526115</pub-id><pub-id pub-id-type="pmid">36170804</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Domislovic M, Domislovic V, Fucek M, et al. Should the CKD EPI equation be used for estimation of the glomerular filtration rate in obese subjects? Kidney Blood Press Res. 2022;47(10):597&#8211;604.<pub-id pub-id-type="pmid">36170804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000526115</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basolo</surname><given-names>A</given-names></name><name name-style="western"><surname>Salvetti</surname><given-names>G</given-names></name><name name-style="western"><surname>Giannese</surname><given-names>D</given-names></name><etal/></person-group><article-title>Obesity, hyperfiltration, and early kidney damage: a new formula for the estimation of creatinine clearance</article-title><source>J Clin Endocrinol Metab</source><year>2023</year><volume>108</volume><issue>12</issue><fpage>3280</fpage><lpage>3286</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgad330</pub-id><pub-id pub-id-type="pmid">37296533</pub-id><pub-id pub-id-type="pmcid">PMC10655541</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Basolo A, Salvetti G, Giannese D, et al. Obesity, hyperfiltration, and early kidney damage: a new formula for the estimation of creatinine clearance. J Clin Endocrinol Metab. 2023;108(12):3280&#8211;6.<pub-id pub-id-type="pmid">37296533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgad330</pub-id><pub-id pub-id-type="pmcid">PMC10655541</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pehlivan</surname><given-names>E</given-names></name><name name-style="western"><surname>Ozen</surname><given-names>G</given-names></name><name name-style="western"><surname>Taskapan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Identifying the determinants of microalbuminuria in obese patients in primary care units: the effects of blood pressure, random plasma glucose and other risk factors</article-title><source>J Endocrinol Invest</source><year>2016</year><volume>39</volume><issue>1</issue><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s40618-015-0331-6</pub-id><pub-id pub-id-type="pmid">26093468</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Pehlivan E, Ozen G, Taskapan H, et al. Identifying the determinants of microalbuminuria in obese patients in primary care units: the effects of blood pressure, random plasma glucose and other risk factors. J Endocrinol Invest. 2016;39(1):73&#8211;82.<pub-id pub-id-type="pmid">26093468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40618-015-0331-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basdevant</surname><given-names>A</given-names></name><name name-style="western"><surname>Cassuto</surname><given-names>D</given-names></name><name name-style="western"><surname>Gibault</surname><given-names>T</given-names></name><etal/></person-group><article-title>Microalbuminuria and body fat distribution in obese subjects</article-title><source>Int J Obes Relat Metab Disord</source><year>1994</year><volume>18</volume><issue>12</issue><fpage>806</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">7894519</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Basdevant A, Cassuto D, Gibault T, et al. Microalbuminuria and body fat distribution in obese subjects. Int J Obes Relat Metab Disord. 1994;18(12):806&#8211;11.<pub-id pub-id-type="pmid">7894519</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>P</given-names></name><name name-style="western"><surname>Lewington</surname><given-names>S</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank</article-title><source>Int J Obes (Lond)</source><year>2020</year><volume>44</volume><issue>11</issue><fpage>2256</fpage><lpage>2266</lpage><pub-id pub-id-type="doi">10.1038/s41366-020-0642-3</pub-id><pub-id pub-id-type="pmid">32678323</pub-id><pub-id pub-id-type="pmcid">PMC7577847</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Zhu P, Lewington S, Haynes R, et al. Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. Int J Obes (Lond). 2020;44(11):2256&#8211;66.<pub-id pub-id-type="pmid">32678323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41366-020-0642-3</pub-id><pub-id pub-id-type="pmcid">PMC7577847</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellini</surname><given-names>MI</given-names></name><name name-style="western"><surname>Nozdrin</surname><given-names>M</given-names></name><name name-style="western"><surname>Pengel</surname><given-names>L</given-names></name><etal/></person-group><article-title>How good is a living donor? Systematic review and meta-analysis of the effect of donor demographics on post kidney transplant outcomes</article-title><source>J Nephrol</source><year>2022</year><volume>35</volume><issue>3</issue><fpage>807</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1007/s40620-021-01231-7</pub-id><pub-id pub-id-type="pmid">35072936</pub-id><pub-id pub-id-type="pmcid">PMC8995249</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Bellini MI, Nozdrin M, Pengel L, et al. How good is a living donor? Systematic review and meta-analysis of the effect of donor demographics on post kidney transplant outcomes. J Nephrol. 2022;35(3):807&#8211;20.<pub-id pub-id-type="pmid">35072936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40620-021-01231-7</pub-id><pub-id pub-id-type="pmcid">PMC8995249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reese</surname><given-names>PP</given-names></name><name name-style="western"><surname>Caplan</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kesselheim</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Creating a medical, ethical, and legal framework for complex living kidney donors</article-title><source>Clin J Am Soc Nephrol</source><year>2006</year><volume>1</volume><issue>6</issue><fpage>1148</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.2215/CJN.02180606</pub-id><pub-id pub-id-type="pmid">17699340</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Reese PP, Caplan AL, Kesselheim AS, et al. Creating a medical, ethical, and legal framework for complex living kidney donors. Clin J Am Soc Nephrol. 2006;1(6):1148&#8211;53.<pub-id pub-id-type="pmid">17699340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.02180606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reese</surname><given-names>PP</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>HI</given-names></name><name name-style="western"><surname>McBride</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Substantial variation in the acceptance of medically complex live kidney donors across US renal transplant centers</article-title><source>Am J Transplant</source><year>2008</year><volume>8</volume><issue>10</issue><fpage>2062</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2008.02361.x</pub-id><pub-id pub-id-type="pmid">18727695</pub-id><pub-id pub-id-type="pmcid">PMC2590588</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Reese PP, Feldman HI, McBride MA, et al. Substantial variation in the acceptance of medically complex live kidney donors across US renal transplant centers. Am J Transplant. 2008;8(10):2062&#8211;70.<pub-id pub-id-type="pmid">18727695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-6143.2008.02361.x</pub-id><pub-id pub-id-type="pmcid">PMC2590588</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>PR</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>J</given-names></name><name name-style="western"><surname>Braga</surname><given-names>PC</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>SS</given-names></name><name name-style="western"><surname>Nora</surname><given-names>M</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>M</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>MP</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>A</given-names></name></person-group><article-title>Renal dysfunction phenotypes in patients undergoing obesity surgery</article-title><source>Biomolecules.</source><year>2023</year><volume>13</volume><issue>5</issue><fpage>790</fpage><pub-id pub-id-type="doi">10.3390/biom13050790</pub-id><pub-id pub-id-type="pmid">37238660</pub-id><pub-id pub-id-type="pmcid">PMC10216106</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Pereira PR, Pereira J, Braga PC, Pereira SS, Nora M, Guimar&#227;es M, Monteiro MP, Rodrigues A. Renal dysfunction phenotypes in patients undergoing obesity surgery. Biomolecules. 2023;13(5):790. 10.3390/biom13050790.<pub-id pub-id-type="pmid">37238660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom13050790</pub-id><pub-id pub-id-type="pmcid">PMC10216106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SM</given-names></name><name name-style="western"><surname>Park</surname><given-names>JY</given-names></name><name name-style="western"><surname>Park</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Association of renal hyperfiltration with incident proteinuria - a nationwide registry study</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><issue>4</issue><fpage>e0195784</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0195784</pub-id><pub-id pub-id-type="pmid">29652920</pub-id><pub-id pub-id-type="pmcid">PMC5898733</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Lee SM, Park JY, Park MS, et al. Association of renal hyperfiltration with incident proteinuria - a nationwide registry study. PLoS ONE. 2018;13(4):e0195784.<pub-id pub-id-type="pmid">29652920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0195784</pub-id><pub-id pub-id-type="pmcid">PMC5898733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortinovis</surname><given-names>M</given-names></name><name name-style="western"><surname>Perico</surname><given-names>N</given-names></name><name name-style="western"><surname>Ruggenenti</surname><given-names>P</given-names></name><etal/></person-group><article-title>Glomerular hyperfiltration</article-title><source>Nat Rev Nephrol</source><year>2022</year><volume>18</volume><issue>7</issue><fpage>435</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1038/s41581-022-00559-y</pub-id><pub-id pub-id-type="pmid">35365815</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Cortinovis M, Perico N, Ruggenenti P, et al. Glomerular hyperfiltration. Nat Rev Nephrol. 2022;18(7):435&#8211;51.<pub-id pub-id-type="pmid">35365815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-022-00559-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazar</surname><given-names>MA</given-names></name></person-group><article-title>Resistin- and obesity-associated metabolic diseases</article-title><source>Horm Metab Res</source><year>2007</year><volume>39</volume><issue>10</issue><fpage>710</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1055/s-2007-985897</pub-id><pub-id pub-id-type="pmid">17952831</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Lazar MA. Resistin- and obesity-associated metabolic diseases. Horm Metab Res. 2007;39(10):710&#8211;6.<pub-id pub-id-type="pmid">17952831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-2007-985897</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourebaba</surname><given-names>L</given-names></name><name name-style="western"><surname>Marycz</surname><given-names>K</given-names></name></person-group><article-title>Pathophysiological implication of fetuin-a glycoprotein in the development of metabolic disorders: A Concise Review</article-title><source>J Clin Med.</source><year>2019</year><volume>8</volume><issue>12</issue><fpage>2033</fpage><pub-id pub-id-type="doi">10.3390/jcm8122033</pub-id><pub-id pub-id-type="pmid">31766373</pub-id><pub-id pub-id-type="pmcid">PMC6947209</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Bourebaba L, Marycz K. Pathophysiological implication of fetuin-a glycoprotein in the development of metabolic disorders: A Concise Review. J Clin Med. 2019;8(12):2033. 10.3390/jcm8122033.<pub-id pub-id-type="pmid">31766373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm8122033</pub-id><pub-id pub-id-type="pmcid">PMC6947209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#246;kenkamp</surname><given-names>A</given-names></name></person-group><article-title>Proteinuria-take a closer look!</article-title><source>Pediatr Nephrol</source><year>2020</year><volume>35</volume><issue>4</issue><fpage>533</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1007/s00467-019-04454-w</pub-id><pub-id pub-id-type="pmid">31925536</pub-id><pub-id pub-id-type="pmcid">PMC7056687</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">B&#246;kenkamp A. Proteinuria-take a closer look! Pediatr Nephrol. 2020;35(4):533&#8211;41.<pub-id pub-id-type="pmid">31925536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00467-019-04454-w</pub-id><pub-id pub-id-type="pmcid">PMC7056687</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>W</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>P</given-names></name><name name-style="western"><surname>Sumida</surname><given-names>K</given-names></name><etal/></person-group><article-title>Association of uric acid-lowering therapy with incident chronic kidney disease</article-title><source>JAMA Netw Open</source><year>2022</year><volume>5</volume><issue>6</issue><fpage>e2215878</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.15878</pub-id><pub-id pub-id-type="pmid">35657621</pub-id><pub-id pub-id-type="pmcid">PMC9166229</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Hassan W, Shrestha P, Sumida K, et al. Association of uric acid-lowering therapy with incident chronic kidney disease. JAMA Netw Open. 2022;5(6):e2215878.<pub-id pub-id-type="pmid">35657621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.15878</pub-id><pub-id pub-id-type="pmcid">PMC9166229</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Kestenbaum</surname><given-names>B</given-names></name></person-group><article-title>Proximal tubular secretory clearance: a neglected partner of kidney function</article-title><source>Clin J Am Soc Nephrol</source><year>2018</year><volume>13</volume><issue>8</issue><fpage>1291</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.2215/CJN.12001017</pub-id><pub-id pub-id-type="pmid">29490976</pub-id><pub-id pub-id-type="pmcid">PMC6086711</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Wang K, Kestenbaum B. Proximal tubular secretory clearance: a neglected partner of kidney function. Clin J Am Soc Nephrol. 2018;13(8):1291&#8211;6.<pub-id pub-id-type="pmid">29490976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.12001017</pub-id><pub-id pub-id-type="pmcid">PMC6086711</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name><name name-style="western"><surname>Choi</surname><given-names>ME</given-names></name></person-group><article-title>Urinary biomarkers for early diabetic nephropathy: beyond albuminuria</article-title><source>Pediatr Nephrol</source><year>2015</year><volume>30</volume><issue>7</issue><fpage>1063</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1007/s00467-014-2888-2</pub-id><pub-id pub-id-type="pmid">25060761</pub-id><pub-id pub-id-type="pmcid">PMC4305495</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Lee SY, Choi ME. Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr Nephrol. 2015;30(7):1063&#8211;75.<pub-id pub-id-type="pmid">25060761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00467-014-2888-2</pub-id><pub-id pub-id-type="pmcid">PMC4305495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jalal</surname><given-names>DI</given-names></name><name name-style="western"><surname>Rivard</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><issue>6</issue><fpage>1865</fpage><lpage>1869</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfp740</pub-id><pub-id pub-id-type="pmid">20064950</pub-id><pub-id pub-id-type="pmcid">PMC2902891</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant. 2010;25(6):1865&#8211;9.<pub-id pub-id-type="pmid">20064950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfp740</pub-id><pub-id pub-id-type="pmcid">PMC2902891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamagata</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>K</given-names></name><name name-style="western"><surname>Sairenchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study</article-title><source>Kidney Int</source><year>2007</year><volume>71</volume><issue>2</issue><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002017</pub-id><pub-id pub-id-type="pmid">17136030</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71(2):159&#8211;66.<pub-id pub-id-type="pmid">17136030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.ki.5002017</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>